Morgan Stanley Maintains Equal-Weight on United Therapeutics, Raises Price Target to $566
Morgan Stanley analyst Terence Flynn maintains United Therapeutics (NASDAQ:UTHR) with a Equal-Weight and raises the price target from $515 to $566.
Share
Why It Matters
A big bank analyst raised their price target for United Therapeutics stock. They still think the stock is fairly priced, not cheap or expensive right now.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.